Cardiovascular Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cardiovascular deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of 563 cardiovascular deals from 2016 to 2024.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of cardiovascular dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in cardiovascular dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the cardiovascular field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in cardiovascular dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of cardiovascular deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of cardiovascular deals listed by therapeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in cardiovascular deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Cardiovascular Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Fully revised and updated, the report provides details of 563 cardiovascular deals from 2016 to 2024.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of cardiovascular dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in cardiovascular dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the cardiovascular field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in cardiovascular dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of cardiovascular deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of cardiovascular deals listed by therapeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in cardiovascular deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Cardiovascular Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse cardiovascular collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Report Scope
Cardiovascular Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cardiovascular trends and structure of deals entered into by leading biopharma companies worldwide.Cardiovascular Collaboration and Licensing Deals includes:
- Trends in cardiovascular dealmaking in the biopharma industry
- Overview of collaboration and licensing deal structure
- Directory of cardiovascular deal records covering pharmaceutical and biotechnology
- The leading cardiovascular deals by value
- Most active cardiovascular licensing dealmakers
In Cardiovascular Collaboration and Licensing Deals, the available deals are listed by:
- Company A-Z
- Headline value
- Therapeutic area
- Technology type
Cardiovascular Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in cardiovascular dealmaking
Chapter 3 - Financial deal terms for cardiovascular partnering
Chapter 4 - Leading cardiovascular deals and dealmakers
Chapter 5 - Cardiovascular contract document directory
Chapter 6 - Cardiovascular dealmaking by therapeutic target
Deal directory
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Molecular Therapeutics
- 23andMe
- A*STAR Agency for Science
- Technology and Research
- Abbisko Therapeutics
- Abbott Laboratories
- Abbott Vascular Devices
- Abbvie
- Acandis
- Acasti Pharma
- Accenture
- AccuLine
- AccurKardia
- ACEA Biosciences
- ACIST Medical Systems
- Actelion
- Acutus Medical
- ADAS 3D Medical
- AddUp
- Adhera Therapeutics
- Admera Health
- Advanced BioInformatics
- Advanced Catheter Therapies
- Adventus Ventures
- Aegerion Pharmaceutical
- Aerolase
- AFFiRiS
- Agena Bioscience
- Agepha Pharma
- AgeX Therapeutics
- Aidoc
- Akcea Therapeutics
- Akebia Therapeutics
- Albert Einstein College of Medicine
- Aleris
- Alexion Pharmaceuticals
- Alibaba Health
- AliveCor
- ALK-Abello
- Allegis Pharmaceuticals
- Allergan
- Allscripts
- Alnylam Pharmaceuticals
- Altamira Therapeutics
- Alyvant
- Amarin
- American College of Cardiology
- American Heart Association
- Amgen
- AMO Pharma
- Amryt Pharma
- AnaBios
- Analog Devices
- AnaMar
- Ancora Heart
- AnGes MG
- Angiogenesis Foundation
- Angion Biomedica
- Angionetics
- AngioSoma
- Antares Pharma
- Antaros Medical
- Anthos Therapeutics
- Anumana
- Apicore
- Aplagon
- Apotex
- Apple
- Aptahem
- Aralez Pharmaceuticals
- Ardelyx
- Arena Pharmaceuticals
- argenx
- Argon Medical Devices
- Armatus Bio
- Arrowhead Pharmaceuticals
- Asahi Kasei
- Aspire Health Science
- Astellas Pharma
- AstraZeneca
- Atelerix
- Athena Bioscience
- Athersys
- Attune Medical
- Audentes Therapeutics
- Australian Research Council
- Autotelic BIO
- Avania
- Avery Therapeutics
- Avicenna Technology
- Avidity Biosciences
- Avinger
- Avrobio
- Axiogenesis
- Axol Bioscience
- B-Secur
- Babraham Institute
- Baxter International
- Bayer
- Bay Labs
- Baylor College
- Beam Therapeutics
- Beijing SL Pharma
- Bened Biomedical
- BenevolentAI
- Beth Israel Deaconess Medical Center
- Bicycle Therapeutics
- BioCardia
- Biocon
- Biofourmis
- BioIntelliSense
- BioLamina
- BioMarin Pharmaceutical
- BioMatrix Specialty Pharmacy
- Biomerics
- BioPep
- BioSig Technologies
- Biotheus
- Biotricity
- Biotronik
- Bioventix
- Biovic Sdn bhd
- Bird Foundation
- Bitterroot Bio
- BiVACOR
- BlueRock Therapeutics
- Blue Water Biotech
- Boehringer Ingelheim
- Boston Medical Center
- Boston Pharmaceuticals
- Boston Scientific
- BridgeBio Pharma
- Brigham and Women's Hospital
- Brigham Young University
- BrightInsight
- Bristol-Myers Squibb
- Broad Institute
- Broncus Technologies
- Butterfly Network
- Cadila Pharmaceuticals
- Caerus Strength
- Caladrius Biosciences
- California Institute of Technology
- Canadian Institutes of Health Research
- Cap Alter Pharma
- Capricor Therapeutics
- Capsule Tech
- CardiaCare
- Cardiac Insight
- Cardialen
- CardieX
- CardiNor
- CardioFocus
- Cardiogen Sciences
- Cardiomatics
- Cardiome Pharma
- Cardiovascular Research Foundation
- Cardiovascular Solutions of Central Mississippi
- Cardiovascular Systems
- Cardiowise
- Cardurion Pharmaceuticals
- Carestream Health
- CareTaker Medical
- Caristo Diagnostics
- Carmat
- Carmel Pharma
- Carrum Health
- Case Western Reserve University
- Catheter Precision
- CathWorks
- CB Scientific
- Ceapro
- Cedars-Sinai Medical Center
- Celanese
- Cell and Gene Therapy Catapult
- CELLINK
- CellProThera
- Cell Therapy
- Celltrion
- Cevec Pharmaceuticals
- Chang Gung University
- Chansu Vascular Technologies
- Charles River Laboratories
- Cheil Pharm
- Children's Heart Foundation
- Children's Hospital Boston
- Children's Hospital of Orange County
- Children's Hospital of Philadelphia
- Children's Medical Research Institute
- Children's Minnesota
- China Grand Pharmaceutical
- Chinese Society of Cardiology
- Cholesgen
- CinCor Pharma
- Cipherome
- Cipher Pharmaceuticals
- Cipla
- Circle cardiovascular imaging
- Citius Pharmaceuticals
- Civica Rx
- Clario
- Cleveland Clinic
- Closed Loop Medicine
- Coala Life
- Columbia University Medical Center
- CoreRx Pharma
- Corindus Vascular Robotics
- Cornell University
- Correvio Pharma
- Corvidia Therapeutics
- Cosette Pharmaceuticals
- Creative Medical Technologies
- Critical Diagnostics
- Crown Bioscience
- CSL
- Curadev Pharma
- CVie
- CyberHeart
- Cyclenium Pharma
- Cyclerion Therapeutics
- Cytokinetics
- Daiichi Sankyo
- Dalhousie University
- Dassault Systems
- Datos Health
- DaVinci Biomedical Research Products
- deCODE Genetics
- Denovium
- Denovo Biopharma
- Department of Defense
- Dewpoint Therapeutics
- DHR Health
- Diablo Clinical Research
- DiA Imaging Analysis
- Dicerna Pharmaceuticals
- DiNAQOR
- DKSH
- DNAnexus
- Dogma Therapeutics
- Dorizoe Lifesciences
- Dr. Reddy's Laboratories
- Duke-NUS Graduate Medical School Singapore
- Duke Clinical Research Institute (DCRI)
- Duke University
- Duke University Medical Center
- Dyno Therapeutics
- Eccogene
- EchoNous
- Edwards Lifesciences
- eGenesis
- Egnite
- Eko
- ELC Group
- Eledon Pharmaceuticals
- Eleven Biotherapeutics
- Elexopharm
- Eligo Bioscience
- Eli Lilly
- Embolx
- Emory University
- Enamine
- Enogenesis
- Enzolytics
- Epsilon
- Er-Kim
- Erasmus University Medical Center
- ERS Genomics
- Esperion Therapeutics
- Espero Biopharma
- Ethris
- Etiometry
- Eureka Eurostars
- European Innovation Council
- European Wellness Biomedical Group
- Everest Medicines
- Evotec
- Evox Therapeutics
- Exo
- Exscientia
- Feinstein Institute for Medical Research
- FEops
- FibriCheck
- Fine Foods & Pharmaceuticals N.T.M.
- FitBit
- Flagship Biosciences
- Flagship Pioneering
- Food and Drug Administration (FDA)
- Forcefield Therapeutics
- Fortress Biotech
- Freeline Therapeutics
- Frontier Biotech
- Fujifilm
- Fujifilm medical systems
- Fuji Yakuhin
- Fulcrum Therapeutics
- G3 Pharmaceuticals
- G3 Therapeutics
- Gatehouse Bio
- GC Pharma
- GE Healthcare
- Geisinger Medical Center
- Gemphire
- Genome Biologics
- Genomic Vision
- George Clinical
- Georgetown University
- Georgia Institute of Technology
- German Ministry for Education and Research
- Gestion Univalor
- Global Genomics Group
- GNS Healthcare
- Government of South Korea
- Grunenthal
- GS
- Guangdong Provincial People's Hospital
- Hainan Sihuan Pharmaceutical
- Handok Pharmaceuticals
- Harvard Stem Cell Institute
- Harvard University
- Hasten Biopharmaceutic
- HAYA Therapeutics
- HCM Registry
- Healios K.K.
- Healium Medical
- Health Recovery Solutions
- Health Sciences Research Institute Germans Trias i Pujol Foundation
- HeartBeam
- Heartflow
- HeartGenetics
- HeartHero
- Heart Rhythm Clinical Research Solutions
- HeartSciences
- Heartseed
- Helix
- Hemostemix
- Henry Ford Health System
- Heqet Therapeutics
- Hetero Labs
- High Desert Heart Institute
- HighLife
- Hikma Pharmaceuticals
- HitGen
- HLS Therapeutics
- Holberg EEG
- HoliStick Medical
- Horizon Discovery
- Horizon Europe
- Hospital for Sick Children
- Huadong Medicine
- Huami
- Huapont Pharma
- Humacyte
- Human Biosystems
- Hyloris Pharmaceuticals
- Icahn School of Medicine at Mount Sinai
- iCardiac Technologies
- Idorsia
- iECURE
- ii Ventures
- Illumina
- ImagineMIC
- IME Medical Electrospinning
- ImpediMed
- Imperial College London
- Imricor Medical Systems
- InCarda Therapeutics
- Indiana University
- InfoBionic.Ai
- inHealth Medical
- inHEART
- Innosuisse
- Innovate UK
- Innovation Network Corporation
- Innova Vascular
- Innovent Biologics
- InQB8 Medical Technologies
- Insilico Biotechnology
- Inspyr Therapeutics
- Institute of Human Virology
- Integrated DNA Technologies
- Intermountain Healthcare
- International Society of Heart and Lung Transplantation
- Ionis Pharmaceuticals
- I Peace
- iRhythm Technology
- Istituti Clinici Scientifici Maugeria
- Itochu
- Ixaka
- Jackson Laboratory
- Jacksonville Pharmaceuticals
- Jana Care
- JanOne
- Janssen Pharmaceuticals
- Janssen Research & Development
- Jarvik Heart
- JenaValve Technology
- Jiangsu Hansoh Pharmaceutical
- Ji Xing Pharmaceuticals
- Johns Hopkins Medicine (JHM)
- Johns Hopkins University
- Juntendo University
- Kahn-Sagol-Maccabi
- Kalos Medical
- Kantonsspital St. Gallen
- Kastle Therapeutics
- Keystone Heart
- Kiniksa Pharmaceuticals
- Kiromic Biopharma
- Kissei Pharmaceutical
- Kitov Pharma
- Kowa
- Kowa Pharmaceuticals America
- Kuhnil Pharmaceuticals
- Kyoto University
- Kyowa Hakko Kirin
- Kyttaro
- Laboratory Corporation of America
- La Jolla Capital
- La Jolla Pharmaceutical
- Lannett
- Lantheus Medical Imaging
- Laurel Bridge Software
- Lee's Pharmaceutical
- Leiden University
- Leonhardt's Launchpads
- LEO Pharma
- Leviticus Cardio
- LEXEO Therapeutics
- Lexington Biosciences
- LianBio
- LIB Therapeutics
- LifeQ
- LifeTech Scientific
- LifeWatch Services
- Ligand Pharmaceuticals
- LindaCare
- Lipigon Pharmaceuticals
- Longeveron
- Lonza
- Lotus Pharmaceuticals
- LSU Health Sciences Center
- LUCA Science
- Lund University
- Luscii
- mAbsolve
- Magnesium Elektron
- Mallinckrodt Pharmaceuticals
- Marizyme
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- Max Biopharma
- Mayo Clinic
- McGill University
- MD Anderson Cancer Center
- MDF Instruments
- Medable
- MedAxiom
- MedCision
- Medicardia Health
- MediciNova
- Medicure
- MedImmune
- Medipal Holdings
- Medis
- Medis Medical Imaging
- Mediso
- Medison Pharma
- Meditrial Europe
- Medtronic
- Melinta Therapeutics
- Menarini
- Mentice
- Merck and Co
- Mesoblast
- Mespere LifeSciences
- Metaba
- MetaSight Diagnostics
- Metrion Biosciences
- Micro Interventional Devices
- Milestone Pharmaceuticals
- Minnetronix
- Mobvoi
- Mochida Pharmaceutical
- Moderna
- Molecular Stethoscope
- Monash University
- Montefiore Health System
- Montreal Heart Institute
- Mperia Therapeutics
- Mpirik
- Munich Reinsurance Company
- Myant
- Myocarditis Foundation
- MyoKardia
- Myriad RBM
- N8 Medical
- Nagoya University Graduate School of Medicine
- NanoSurface Biomedical
- NASA
- Nashville Biosciences
- National Cancer Center
- National Cancer Institute
- National Center for Cardiovascular Diseases
- National Cerebral and Cardiovascular Disease Research Center
- National Heart
- Lung and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Institute on Aging
- National Institutes of Health
- National Organization for Rare Disorders
- National Physical Laboratory
- National University of Ireland
- Galway (NUI Galway)
- Nationwide Children’s Hospital
- Natus Medical
- Ncardia
- NeoChord
- Neomorph
- Neovasc
- Neurimmune Therapeutics
- NeuroproteXeon
- New American Therapeutics
- NewAmsterdam Pharma
- New Wave Ventures
- New York Institute of Technology
- NGM Biopharmaceuticals
- NHS Scotland
- Nightingale Health
- NIMIUM Therapeutics
- Ninety One
- Nissan Chemical Industries
- North Carolina State University
- Northwestern Medicine Bluhm Cardiovascular Institute
- Northwestern Medicine Developmental Therapeutics Institute
- NovalGen
- Novartis
- Novocardia
- Novoheart
- Novo Nordisk
- Novostia
- NTT Data
- NTT Medical Center Tokyo
- Numares
- Numerate
- Nxera Pharma
- Octapharma
- Ohio State University
- OliX Pharmaceuticals
- OMEICOS Therapeutics
- Omron
- OncoImmune
- One Drop
- OnFace
- OptiBiotix
- Optina Diagnostics
- Opus Medical
- Orchestra BioMed
- Orebro University
- Organicell Regenerative Medicine
- ORIG3N
- Oscor
- OSE Immunotherapeutics
- Otsuka
- Ovation
- Owkin
- PaceMate
- Paion
- Paragonix Technologies
- Paraza Pharma
- Paul G Allen Family Foundation
- Peijia Medical
- Peking University
- Penn Medicine
- PeptiDream
- Pfizer
- PharmAbcine
- Pharmabiota
- Pharmanovia
- Pharma Scientific Research
- Pharmazz
- Pharnext
- PhaseBio Pharmaceuticals
- Phibro Animal Health
- Philips
- Phlox Therapeutics
- PhoreMost
- PhysIQ
- Pierre Fabre
- Pilloxa
- PlaqueTec
- Pluriomics
- Pluristem Therapeutics
- Pohl Boskamp
- Population Health Research Institute
- Precision BioSciences
- Precision Image Analysis
- Premier Inc
- Prevail InfoWorks
- Prevencio
- Primary Peptides
- Primordial Genetics
- Procella Therapeutics
- Profil Institute for Clinical Research
- Profusa
- Project HOPE
- ProtoKinetix
- PulseCath
- Punjab Province
- Qilu Pharmaceutical
- Qingdao Primedicine Pharmaceutical
- Qualigen
- Quercis Pharma
- Quest Diagnostics
- Quotient Therapeutics
- Rain Oncology
- Rancho Santa Fe Bio
- Recordati
- ReCor Medical
- Redoxis
- Redwire
- Regenerative Care Network
- Regenerative Medicine of Latin America
- Regeneron Pharmaceuticals
- Regenxbio
- Regio Biosciences
- Rejuvenate Bio
- Relaxera Pharmazeutische
- Reliance Life Sciences
- Renova Therapeutics
- Research Development Foundation
- Resverlogix
- Retia Medical
- Revive Therapeutics
- Rexgenero
- Rex Medical
- Rigel Pharmaceuticals
- Riparian Pharmaceuticals
- Roche
- Roche Diagnostics
- Rocket Pharmaceuticals
- Roivant Sciences
- Royal Philips Electronics
- RTW Investments
- Rutgers University
- SACCO
- Samsung Biologics
- Samsung Electronics
- Sana Klinikum Offenbach
- SandboxAQ
- Sandoz
- SanegeneBio
- Sanofi
- Sarepta Therapeutics
- SCIMAGE
- ScinoPharm Taiwan
- Scipher Medicine
- Scohia Pharma
- scPharmaceuticals
- Seattle Childrens Research Institute
- Secant Medical
- Secarna Pharmaceuticals
- Sema4
- Semmelweis University
- Sensifree
- Senti Biosciences
- Seqirus
- SERB Pharmaceuticals
- SFJ Pharmaceuticals
- Shanghai Argo Biopharmaceutical
- Shanghai Model Organisms Center
- Shenzhen Salubris Pharmaceuticals
- Shenzhen Semacare Medical Technology
- Shire Pharmaceuticals
- Siemens Healthineers
- SignPath Pharmaceuticals
- Silence Therapeutics
- Sinomed
- Sirtex Medical
- SkylineDX
- Skyline Therapeutics
- SmartCella
- Smartwise
- SNBL CPC
- Societal CDMO
- Society of NeuroInterventional Surgery
- Society of Vascular and Interventional Neurology
- Solid Biosciences
- SomaLogic
- SonoScape Medical
- SOPHiA Genetics
- Sosei
- Sosei Heptares
- Soundbite Medical
- Southwest Research Institute
- Sphingotec
- SQI Diagnostics
- SQ Innovation
- Standard BioTools
- Stanford University
- Stanford University School of Medicine
- Staten Biotechnology
- Stealth BioTherapeutics
- StemCardia
- Stempeutics
- STENTiT
- Stereotaxis
- StrideBio
- Sumocor
- Surge Cardiovascular
- SurModics
- Suzhou Ribo Life Sciences
- Swedish Bactiguard
- SymphonyAI
- SynAct Pharma
- Syneos Health
- Syntach
- Takeda Pharmaceutical
- Talis Biomedical
- TARA Biosystems
- Taros Chemicals
- Tasly Pharmaceuticals
- Terumo
- Terumo Cardiovascular Systems
- Teson Pharma
- Texas Instruments
- TGen Drug Development
- The Foundry
- TheraVasc
- The University of Chicago Medicine
- Third Pole Therapeutics
- Toray
- toSense
- Transgenomic
- Triple Ring Technologies
- Tris Pharma
- TTP Group
- twoXAR
- UAB Research Foundation
- Ubiquigent
- Ultragenyx Pharmaceuticals
- UltraSight
- Ultromics
- Unilife
- UniQure
- United Imaging Healthcare
- United Therapeutics
- University College London
- University of Bern
- University of British Columbia
- University of California
- San Diego
- University of California Los Angeles
- University of California San Francisco
- University of Cambridge
- University of Cincinnati
- University of Colorado
- University of Erlangen
- University of Glasgow
- University of Iowa
- University of Lausanne
- University of Manchester
- University of Maryland
- University of Miami
- University of Nebraska
- University of Oslo
- University of Oxford
- University of Pennsylvania
- University of Pittsburgh
- University of the Highlands and Islands
- University of Utah Research Foundation
- University of Washington
- University of West Indies
- University of Wisconsin-Madison
- Us2.ai
- Valo Health
- Vascugen
- Vascular Flow Technologies
- Vasomune Therapeutics
- Vastrax
- VectraCor
- Venturis Therapeutics
- Venus Medtech
- Verantos
- Verily
- Verity Pharmaceuticals
- Verizon
- Verve Therapeutics
- VFLO Medical
- Viatris
- Vifor Pharma
- Vince & Associates Clinical Research
- Vincere Biosciences
- Visirna Therapeutics
- Vitro Biopharma
- Viva Biotech
- VivaQuant
- Vivasc Therapeutics
- VivoSense
- Viz.ai
- Vizient
- Volta Medical
- VOTIS Subdermal Imaging Technologies
- Voyager Therapeutics
- Wacker Biotech
- Wake Forest University
- WakeMed Health & Hospitals
- Wallace H. Coulter Foundation
- Washington University in St Louis
- Weill Cornell Medical College
- WellDoc
- Western New England University
- West Pharmaceutical Services
- Windtree Therapeutics
- Winthrop-University Hospital
- World Heart Federation
- WraSer Pharmaceuticals
- Xspire Pharma
- XyloCor Therapeutics
- Yale School of Medicine
- Yale University
- YolTech Therapeutics
- ZAO Firma Euroservice
- ZeClinics
- Zelira Therapeutics
- Zhittya Genesis Medicine
- Zoll Medical
- Zora Biosciences
- Zylox Tonbridge Medical Technology Co
- Ltd
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
